Elan and Transition Therapeutics Receive Key Patent for Alzheimer’s Disease Treatment with ELND005

News   Apr 24, 2009

 
Elan and Transition Therapeutics Receive Key Patent for Alzheimer’s Disease Treatment with ELND005
 
 
 

RELATED ARTICLES

Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization

News

Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..

READ MORE

Computer Program Helps Find Ways to Repurpose Existing Drugs

News

Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.

READ MORE

Machine Learning: Helping Determine How a Drug Affects the Brain

News

Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE